PLUS news

EPLUS Inc. filed a certificate of amendment to its articles of incorporation to increase authorized shares to 77 million, from 75 million common and up to 2 million preferred stock. This strategic move enhances financial flexibility for potential future equity transactions.

ePlus reported Q1 FY27 net sales of $649.1 million, down 1.5% in gross profit, driven by product mix shifts and a memory chip shortage but supported by record recurring revenue. The firm retained its fiscal 2027 full-year guidance.

Plus Therapeutics Inc. has amended its certificate of incorporation to change its corporate name to Cerenome Inc. as of Aug. 3, 2026.

ePlus Inc. appointed John Lutz to its Board of Directors, where he will serve on the Audit and Compensation Committees. His extensive background in global technology operations is expected to support the company's strategic oversight.

ePlus achieved double-digit growth across key metrics with net sales reaching $2.44 billion and adjusted EBITDA of $204.8 million in fiscal 2026, while increasing its quarterly dividend by 8%. The company's strong execution and $411 million cash position demonstrate operational leverage and sharehol…